Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 28, 2017 - Issue 3
Submit an article Journal homepage
712
Views
12
CrossRef citations to date
0
Altmetric
Psoriasis & Related Studies

Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis

April W. ArmstrongKeck School of Medicine, University of Southern California, Los Angeles, CA, USA; Correspondence[email protected]
,
Steven R. FeldmanWake Forest Baptist Medical Center, Winston-Salem, NC, USA;
,
Neil J. KormanUniversity Hospitals Case Medical Center, Cleveland, OH, USA;
,
Xiangyi MengNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA
,
Adriana GuanaNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA
,
Judit NyiradyNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA
,
Vivian HerreraNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA
&
Yang ZhaoNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA
 show all
Pages 200-205 | Received 06 Apr 2016, Accepted 12 Jul 2016, Published online: 19 Aug 2016

References

  • Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151:651–8.
  • Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149:1180-5. Erratum in: JAMA Dermatol. 2014;150:103; JAMA Dermatol. 2014;150:337.
  • Armstrong AW, Schupp C, Bebo B. Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011. Dermatology (Basel). 2012;225:121–6.
  • Kimball AB, Gieler U, Linder D, et al. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol. 2010;24:989–1004.
  • Warren RB, Kleyn CE, Gulliver WP. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol. 2011;164 Suppl 1:1–14.
  • Augustin M. Cumulative life course impairment: identifying patients at risk. Curr Probl Dermatol. 2013;44:74–81.
  • Mattei PL, Corey KC, Kimball AB. Cumulative life course impairment: evidence for psoriasis. Curr Probl Dermatol. 2013;44:82–90.
  • Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004;51:563–9.
  • Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64:ii65–8.
  • Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2:52ra72.
  • Cosentyx [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2015.
  • Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371:326–38.
  • Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2014;29:1082–90.
  • Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172:484–93.
  • Enbrel [package insert]. Thousand Oaks, CA: Immunex Corporation, 2013.
  • Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238–44.
  • Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–16.
  • Joerger M, Huitema AD, Krähenbühl S, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer. 2010;102:673–7.
  • Sugimoto K, Moriyasu F, Saito K, et al. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US. Liver Int. 2013;33:605–15.
  • Uhlenhake EE, Kurkowski D, Feldman SR. Conversations on psoriasis-what patients want and what physicians can provide: a qualitative look at patient and physician expectations. J Dermatolog Treat. 2010;21:6–12.
  • Feldman SR. Approaching psoriasis differently: patient–physician relationships, patient education and choosing the right topical vehicle. J Drugs Dermatol. 2010;9: 908–11.
  • Gottlieb AB, Armstrong AW. Psoriasis outcome measures: a report from the GRAPPA 2012 annual meeting. J Rheumatol. 2013;40:1428–33.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.